RxDoctor Payments Data

Raquibul Islam, MD

Internal Medicine · Chester, PANPI 1174577035

Payments from drug & device makers

$242in general payments, 2019–2025

Across 15 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$59
  • Novo Nordisk$48
  • Lilly USA, LLC$44
  • AbbVie$25
  • Astellas Pharma US Inc$22
  • GSK$17
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$242100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$242 in reported general payments places this provider in the 55th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$991
Medicare patients
17
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala96$368,830
TriumeqAbacavir/Dolutegravir/Lamivudi22$145,657
GenvoyaElviteg/Cob/Emtri/Tenof Alafen35$130,594
JanuviaSitagliptin Phosphate158$105,520
TrulicityDulaglutide82$93,817
JardianceEmpagliflozin85$72,937
EliquisApixaban102$62,945
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf12$56,397
FarxigaDapagliflozin Propanediol76$50,173
Breo ElliptaFluticasone/Vilanterol121$47,499
DuleraMometasone/Formoterol101$34,054
IsentressRaltegravir Potassium15$31,930
XareltoRivaroxaban56$31,068
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$27,911
OzempicSemaglutide26$24,752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Dulera, Isentress, Janumet$13$178,486287 claims
Viiv Healthcare CompanyTriumeq$59$145,65722 claims
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta, Arnuity Ellipta$17$103,363262 claims
Lilly USA, LLCTrulicity$44$93,81782 claims
Novo NordiskOzempic$48$24,75226 claims
AbbVieLinzess$25$14,15227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Chester

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →